MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
A recent JAMA study underscores racial disparities in genetic test access, which UPenn's Basser Center aims to address through its Black & BRCA initiative.
Results from Keynote-522's new interim analysis address several key concerns that prompted the FDA's delayed decision, but other questions remain.
The firm is changing its name and therapeutic focus ahead of a planned IND filing for its RNA-based OligoPhore therapy for KRAS-mutant CRC.
A pilot study out of the Children's Hospital of Philadelphia assessed a humanized anti-CD19 CAR T-cell therapy as a possible way to mitigate treatment resistance.
USC researchers are sequencing Black, Latino, and Asian families in California and plan to study environmental causes for why they are more likely to inherit early-onset cancers.
In a new study, Dana-Farber researchers and collaborators explain the myriad molecular reasons why KRAS-mutated cancers develop resistance to targeted therapy.
The researchers at the startup have developed a microarray test to predict patients' response to chemotherapy based on chromatin accessibility.
Lifileucel's BLA is again delayed, but a 33-month update from a pivotal melanoma trial, along with early data from a frontline study, show continued potential.
Studies of two CAR T-cell products showed encouraging response rates but raised questions about where CD20 targeting fits into lymphoma treatment sequencing.